Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (281-290 of 785) with videos related to

Pageof 79
Sort By:
Kidney International. Supplement|April 16, 2003
Fabry disease: diagnosis and treatmentFrank Breunig, Frank Weidemann, Meinrad Beer, et al.
BMJ Open Diabetes Research & Care|July 5, 2022
Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuriaJanet B McGill, Hermann Haller, Prabir Roy-Chaudhury, et al.
CJC Open|July 19, 2024
Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME TrialAyodele Odutayo, Bernard Zinman, Christoph Wanner, et al.
Kidney International|July 5, 2024
Clinical trial designs to assess treatment effects on glomerular filtration rate declineHiddo J L Heerspink, Dustin J Little, Lars Frison, et al.
BMJ Open|April 10, 2016
Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313YDaniel Oder, Nurcan Üçeyler, Dan Liu, et al.
Kidney Medicine|February 29, 2024
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME TrialSamy Hadjadj, Mark E Cooper, Dominik Steubl, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Impact of vitamin A on clinical outcomes in haemodialysis patientsKatharina M Espe, Jens Raila, Andrea Henze, et al.
Circulation|August 10, 2005
Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout miceSusanne B Schwedler, Kerstin Amann, Konstanze Wernicke, et al.
Plos One|January 30, 2014
Increased arterial diameters in the posterior cerebral circulation in men with Fabry diseaseNurcan Uçeyler, György A Homola, Hans Guerrero González, et al.
Orphanet Journal of Rare Diseases|August 7, 2013
Fibrosis: a key feature of Fabry disease with potential therapeutic implicationsFrank Weidemann, Maria D Sanchez-Niño, Juan Politei, et al.
Pageof 79

Showing results (281-290 of 785) with videos related to

Sort By:
Pageof 79
Kidney International. Supplement|April 16, 2003
Fabry disease: diagnosis and treatmentFrank Breunig, Frank Weidemann, Meinrad Beer, et al.
BMJ Open Diabetes Research & Care|July 5, 2022
Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuriaJanet B McGill, Hermann Haller, Prabir Roy-Chaudhury, et al.
CJC Open|July 19, 2024
Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME TrialAyodele Odutayo, Bernard Zinman, Christoph Wanner, et al.
Kidney International|July 5, 2024
Clinical trial designs to assess treatment effects on glomerular filtration rate declineHiddo J L Heerspink, Dustin J Little, Lars Frison, et al.
BMJ Open|April 10, 2016
Organ manifestations and long-term outcome of Fabry disease in patients with the GLA haplotype D313YDaniel Oder, Nurcan Üçeyler, Dan Liu, et al.
Kidney Medicine|February 29, 2024
Empagliflozin and Rapid Kidney Function Decline Incidence in Type 2 Diabetes: An Exploratory Analysis From the EMPA-REG OUTCOME TrialSamy Hadjadj, Mark E Cooper, Dominik Steubl, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 6, 2011
Impact of vitamin A on clinical outcomes in haemodialysis patientsKatharina M Espe, Jens Raila, Andrea Henze, et al.
Circulation|August 10, 2005
Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout miceSusanne B Schwedler, Kerstin Amann, Konstanze Wernicke, et al.
Plos One|January 30, 2014
Increased arterial diameters in the posterior cerebral circulation in men with Fabry diseaseNurcan Uçeyler, György A Homola, Hans Guerrero González, et al.
Orphanet Journal of Rare Diseases|August 7, 2013
Fibrosis: a key feature of Fabry disease with potential therapeutic implicationsFrank Weidemann, Maria D Sanchez-Niño, Juan Politei, et al.
Pageof 79